Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection

Antivir Ther. 2013;18(7):945-8. doi: 10.3851/IMP2649. Epub 2013 Jul 10.

Abstract

Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection. Although associated with renal toxicity in HIV-infected patients, renal dysfunction has been reported rarely in the monoinfected CHB population. To date, TDF-associated Fanconi syndrome has not been reported. Here, we present two cases of TDF-associated Fanconi syndrome with rapid resolution after its cessation. We then discuss risk factors for TDF nephrotoxicity and its implications for screening for renal disease in those patients with CHB monoinfection on TDF, and the use of TDF in at-risk populations.

Publication types

  • Case Reports

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Biopsy
  • Creatinine / blood
  • Fanconi Syndrome / chemically induced*
  • Fanconi Syndrome / diagnosis
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Kidney / drug effects
  • Kidney / pathology
  • Kidney / physiopathology
  • Kidney / ultrastructure
  • Male
  • Middle Aged
  • Organophosphonates / adverse effects*
  • Organophosphonates / therapeutic use
  • Phosphates / blood
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Tenofovir

Substances

  • Antiviral Agents
  • Organophosphonates
  • Phosphates
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Creatinine
  • Adenine